Intravitreal Conbercept After Vitrectomy

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

March 30, 2018

Study Completion Date

February 28, 2019

Conditions
Early Proliferative Diabetic Retinopathy
Interventions
DRUG

Conbercept

Three-port 25-G PPV was performed in all patients using a Constellation system. Patients in the treatment group received an intravitreal injection of conbercept (10 mg/mL, 0.5 mg) using a sterile technique after 25-G vitrectomy.

All Listed Sponsors
lead

Tianjin Medical University Eye Hospital

OTHER

NCT03426540 - Intravitreal Conbercept After Vitrectomy | Biotech Hunter | Biotech Hunter